Thymogen is a dipeptide, a peptide of two amino acids, built from glutamic acid and tryptophan [1][3]. It is one of the shortest members of the thymic peptide family, a group of short peptides derived from thymus tissue and studied for their effects on T cells, the white blood cells that coordinate the adaptive immune response [1]. The same molecule was studied as an angiogenesis inhibitor, a drug that blocks new blood-vessel growth, under the names IM862 and oglufanide [15][17][18]. It is strongly water-soluble and crosses cell membranes poorly, a combination that has made delivery the practical problem in its literature [26]. The American trials used nasal drops [15][17], and chemists later conjugated the dipeptide to lipids and sugars to improve absorption [26].
Morozov and Khavinson at the Institute of Bioregulation and Gerontology in St Petersburg isolated the dipeptide from Thymalin, a peptide complex extracted from calf thymus, and designed a synthetic drug from it; they reported the work in 1997 [1]. Thymalin had already entered medical practice as an immune corrector, and the dipeptide became the defined, synthetic version of the same idea [1]. The natural form occurs in the thymus, the organ behind the breastbone where T cells mature, and the dipeptide was identified in the soluble fraction of thymic tissue [1][6]. Thymalin is a mixture of peptides rather than a single protein, so it has no single amino-acid length, while Thymogen is exactly two residues [1][3].
The research potential sits in two places: restoring immune cell numbers after chemotherapy or surgery [3][12], and interfering with the signals that feed inflammation and tumor blood supply [4][6][17]. The 2024 review records Thymogen's registration in Russia under certificate P N002408/01 dated June 10, 2009 [3]. As of October 2026, it has no FDA approval on record and does not appear on FDA's Category 2 list [25][24]. Neither the 2026 WADA list nor the NCAA 2026-27 list names it [22][23]. The American oncology program produced a negative phase III result [16]; later work kept its immune-restoration focus [3].
Key takeaways
- Thymogen is a two-amino-acid thymic dipeptide that Russian clinicians have used since the early 1990s, including before surgery and for respiratory infection prevention, to support T-cell immunity [1][12][13].
- The same molecule, called IM862, shrank Kaposi sarcoma lesions in an early trial but failed a 202-patient phase III trial and produced no objective responses in kidney cancer [15][16][17].
- Laboratory work ties its activity to natural killer cells, cytokine output and antioxidant defense [6][4][8]. The molecular basis of that signaling is still unresolved [4][3].
How it works
T cells, neutrophils and the thymic signal
Thymogen is studied as a signal that pushes immature lymphocytes toward mature, working T cells. A lymphocyte is a white blood cell of the adaptive immune system, and T-cell differentiation is the process by which a precursor acquires the receptors and tools of a mature T cell. The 1997 report from the group that developed the drug says the dipeptide activated T-cell differentiation and T-cell recognition of peptide-MHC complexes, the molecular display that lets a T cell see what an infected cell is carrying [1]. The same report describes changes in intracellular cyclic nucleotides, the small messenger molecules that carry signals inside cells, and in the release of interleukin-2 and interferon by blood lymphocytes [1].
The fast-acting side of the immune response also responds. Neutrophils are the white blood cells that arrive first at an infection and engulf bacteria, and chemotaxis is their directed movement toward a chemical signal. In the same report, the synthetic dipeptides activated neutrophil chemotaxis and phagocytosis, the engulfing step [1]. The authors also describe the thymic peptides as cytokine antagonists, meaning they can oppose the action of inflammatory cytokines, and they note that the synthetic dipeptides did not change the antioxidant response in thymocytes, unlike the natural peptides [1].
Cell-culture work adds a growth and adhesion signal. In THP-1 cells, a human leukemia line that can be matured into macrophage-like cells, Thymogen increased tyrosine phosphorylation of mitogen-activated protein kinases, enzymes on a central growth and stress pathway [4]. Phosphorylation is the addition of a phosphate group that switches a protein on. The same study found that Thymogen and four related peptides lowered tumor necrosis factor and interleukin-6 released after bacterial lipopolysaccharide, the bacterial endotoxin used to mimic infection [4]. Thymogen was the most effective of the five at cutting interleukin-17 release, and it reduced monocyte adhesion to activated endothelial cells [4].
Natural killer cells and tumor surveillance
The clearest mechanistic result comes from mouse tumor models. Natural killer cells, or NK cells, are lymphocytes that kill abnormal cells without prior exposure, and perforin is the pore-forming protein they use to do it. The dipeptide inhibited tumor growth in mice without direct toxicity to a panel of human tumor cell lines [6].
The antitumor effect depended on the killing machinery. It disappeared in mice whose NK cells could not traffic their cytotoxic granules, and it disappeared completely in mice lacking perforin [6]. The peptide kept full activity in mice lacking interferon gamma but lost much of it in mice lacking interleukin-12, so the effect runs through NK or NKT cytolytic activity and only partly through interleukin-12 [6]. Interferon gamma and interleukin-12 are cytokines that tune NK-cell killing.
Hematopoietic progenitors are the bone-marrow cells that give rise to all blood cells, and the CFU-S assay counts the more primitive ones by their ability to form spleen colonies. In intact mice, the all-L dipeptide did not change progenitor proliferation, while the D-amino-acid isomers inhibited it and one gamma-bonded isomer stimulated a subset [7]. After irradiation, injecting the L form promoted recovery of the progenitor population, which ties the immune story to marrow regeneration [7].
Inflammation, endothelium and oxidative stress
The dipeptide shows anti-inflammatory effects at the vessel wall. Endothelium is the single layer of cells lining blood vessels, and ICAM-1 is the adhesion molecule that lets white cells grip that lining. In EA.hy 926 endothelial cells, alpha-glutamyl-tryptophan reduced TNF-alpha-induced interleukin-1 alpha, and in peripheral blood mononuclear cells from healthy donors it reduced TNF-alpha-induced interleukin-8, both inflammatory cytokines [5]. The same preparation raised TNF-stimulated ICAM-1 on endothelial cells and the spontaneous level on mononuclear cells, a mixed result the authors read as stronger immune-cell engagement alongside dampened cytokine release [5].
The peptide also touches blood-vessel tone through angiotensin-converting enzyme, or ACE, the enzyme that produces the vasoconstrictor angiotensin II. In human umbilical vein endothelial cells, glutamic acid-tryptophan was the second-strongest ACE inhibitor among three tryptophan-containing peptides [27]. In rat aorta it did not change resting tone but blocked angiotensin I-induced constriction, and in treated hypertensive rats the related peptide isoleucine-tryptophan improved endothelium-dependent relaxation [27]. The authors framed the peptides as food additives [27].
Several animal models show antioxidant effects. Lipid peroxidation is the chain reaction in which reactive oxygen species damage membrane fats, and malondialdehyde is its standard marker. In rats given hydrazine, a chemical that injures the liver, Thymogen at 10 and 100 micrograms per kilogram lowered lipid peroxidation and stimulated hepatocyte regeneration, with no extra benefit at the higher dose [8]. In the carbon tetrachloride model the same pattern appeared, and D-alanine analogues did better than the parent dipeptide [9]. In acute pancreatitis and peritonitis, intraperitoneal Thymogen lowered malondialdehyde, preserved superoxide dismutase and catalase activity, and reduced the leukocyte intoxication index [10].
Chromatin, stem cells and the mechanism question
Thymogen's pharmacology is best described through cell behavior. The molecular structure of the peptide's signaling is still not completely understood, so the account rests on what immune cells, marrow progenitors and tumor models do when the peptide is present [4][3].
The 2024 review proposes an unusual route. It reports that, in a culture of human mesenchymal and hematopoietic stem cells, Thymogen binds the promoter region of the DNA double helix in lymphocyte cells, and it suggests that this binding turns silent heterochromatin into active euchromatin [3]. Heterochromatin is tightly packed DNA that is not being read, and euchromatin is the open form that transcription factors can reach. A promoter is the stretch of DNA where transcription begins. If the observation holds, the dipeptide would act at the chromatin level as well as at surface receptors.
Structure-activity work shows how sensitive the activity is to shape. The L form is the immunostimulant and the D form the immunosuppressor [3]; in marrow, the D forms suppressed progenitor proliferation while the L form promoted recovery after irradiation [7]. The review treats that reciprocal behavior as evidence of a specific, stereoselective target and identifies CD4 and CD8 receptors on T lymphocytes as the Thymogen target [3]. The review presents the pair as the first examples of up-and-down homeostasis regulation by two enantiomeric drugs [3].
What has been studied in humans
Human testing of Thymogen splits into two literatures. Russian investigators studied it as an immune corrector in surgery, respiratory infection prevention and pancreatitis, and American investigators studied the same molecule as the angiogenesis inhibitor IM862 in cancer [12][13][15]. The Russian studies are small and mostly published in Russian, and the two abstracts with clinical detail report immune measurements alongside clinical change [12][14].
The strongest Russian trial is the 2011 double-blind, randomized, placebo-controlled study in elderly patients scheduled for surgery on solid tumors of the abdomen and retroperitoneum [12]. Participants received Thymogen by nasal instillation for seven days before surgery, and the placebo group received saline on the same schedule [12]. The authors report restoration of the structural and functional parameters of cellular immunity, a significant decrease in the number and range of postoperative complications, and a shorter postoperative period [12]. The abstract gives no group sizes, no complication rates and no statistics, so the size of the benefit cannot be judged from it.
Two earlier Russian studies point the same way. In a training military unit, intranasal and subcutaneous Thymogen reduced the morbidity, severity and duration of influenza and other acute respiratory infections, according to a 1993 clinico-epidemiological report [13]. In 48 patients with acute pancreatitis compared with 36 healthy donors, a treatment course corrected the T-cell deficiency and was associated with positive clinical change [14]. Neither abstract describes a placebo comparison, and neither gives response rates.
The American program produced early results in a 2000 randomized phase II trial of intranasal IM862 in 44 patients with AIDS-related Kaposi sarcoma [15]. Major responses occurred in 36 percent, five complete and 11 partial, after a median of 6 weeks, and 21 patients had stable disease [15]. Adverse effects were limited to mild, transient headache, fatigue, tingling and nausea, with no hematologic toxicity attributed to treatment [15]. Seventy-five percent of participants had prior systemic chemotherapy and all but five were taking protease inhibitors, which are HIV drugs, so the contribution of antiretroviral therapy was not separated from the drug effect.
The phase III trial settled the question for Kaposi sarcoma. It randomized 202 HIV-positive patients to intranasal IM862 or placebo in a 24-week trial and found response rates of 23 percent on IM862 and 21 percent on placebo, a difference that was not significant [16]. Time to response was shorter on the drug, 8.5 versus 14 weeks, but median time to progression was also shorter, 16 versus 35 weeks, and the authors concluded that IM862 may accelerate progression [16]. They also noted that highly active antiretroviral therapy alone produced a substantial rate of sustained tumor response, which may have inflated the earlier single-arm results [16].
Kidney cancer produced the same answer. In 25 patients with metastatic renal cell carcinoma, intranasal IM862 in 8-week cycles produced no objective responses, eight patients had stable disease and 17 progressed [17]. There was no grade 2 or 3 toxicity, and plasma vascular endothelial growth factor fell at 4 and 8 weeks, which supports a biological effect without a clinical one [17]. The registries add three studies with no posted results: a completed 43-patient phase I trial in recurrent ovarian cancer, a phase II colorectal trial terminated because the drug was unavailable, and a phase II ovarian trial whose status is unknown [18][19][20].
Doses studied in human trials
As of October 2026, the most recent source reviewed records Thymogen as a Russian-registered medicine, and no FDA approval is on record. Regimens below are those reported in the cited human trials.
Intranasal Thymogen 100 mg once daily for 7 days before surgery; placebo was saline on the same schedule
Elderly patients scheduled for surgery on solid tumors of the abdominal cavity and retroperitoneal space
0.5 to 0.8 mg for the treatment course; route not stated in the abstract
48 patients with acute pancreatitis and 36 healthy donors
IM862 5 mg intranasal daily for 5 days followed by 5 days off, or 5 mg intranasal every other day, in repeated cycles
44 patients with AIDS-related Kaposi sarcoma, median age 38, 75 percent with prior systemic chemotherapy
IM862 5 mg intranasal every other day for 24 weeks
202 HIV-positive patients with AIDS-related Kaposi sarcoma, 104 on IM862 and 98 on placebo
IM862 20 mg intranasal three times daily in 8-week cycles
25 patients with metastatic renal cell carcinoma, median age 62
Lab and animal studies
Animal work covers aging, liver injury, acute abdominal inflammation, heart ischemia and marrow recovery. The longest experiment followed 76 five-month-old female rats for life, with 44 animals receiving 5 micrograms of the dipeptide subcutaneously five times a week for 12 months and 32 receiving saline [2]. Maximum lifespan of the longest-lived 10 percent rose from 949 to 1048 days, the Gompertz aging rate fell from 0.0071 to 0.0041 per day, total tumor incidence was 1.5 times lower and leukemia and lymphoma incidence 3.4 times lower [2]. The abstract does not state whether tumor assessment was blinded, and the work used one outbred rat population.
Liver injury produced the most consistent recent results. Hydrazine hydrochloride given intraperitoneally lowers catalase and raises malondialdehyde, a pattern of oxidative stress, and Thymogen at 10 and 100 micrograms per kilogram lowered lipid peroxidation and stimulated hepatocyte regeneration, with no extra benefit at the higher dose [8]. A second model used five days of intragastric carbon tetrachloride to produce fatty degeneration, and Thymogen suppressed lipid peroxidation and supported repair, while D-alanine analogues did better [9]. Adding D-alanine to the C-terminus gave the strongest effect in both models [8][9], and raising the dose did not add benefit [8].
Acute abdominal disease and the heart were tested in the 1990s. In male albino rats with acute pancreatitis or peritonitis, intraperitoneal Thymogen started early and repeated every 24 hours for five days lowered serum amylolytic activity, malondialdehyde, leukocytosis and the leukocyte intoxication index, and it blunted the fall in superoxide dismutase and catalase [10]. In an isolated heart subjected to ischemia and reperfusion, Thymogen protected the muscle better than dalargin or verapamil, and the authors state that the protection does not run through opioid receptors or calcium-channel blockade [11]. Ischemia is the loss of blood supply and reperfusion is its return, the moment when much of the damage occurs. An isolated heart has no immune system or circulating blood, so this result points to a direct effect on heart tissue.
Cell and vessel experiments fill in the signaling. In EA.hy 926 endothelial cells, alpha-glutamyl-tryptophan lowered TNF-alpha-induced interleukin-1 alpha, and in donor mononuclear cells it lowered TNF-alpha-induced interleukin-8 while raising the spontaneous level of ICAM-1 [5]. In THP-1 monocytes, Thymogen and three of the other four peptides increased ERK1/2 phosphorylation, all five reduced lipopolysaccharide-driven tumor necrosis factor and interleukin-6, and Thymogen was the most effective at lowering interleukin-17 [4]. In human umbilical vein endothelial cells, glutamic acid-tryptophan inhibited angiotensin-converting enzyme, and in rat aorta it blocked angiotensin I-induced constriction without changing resting tone [27].
Absorption is the practical limit. The dipeptide is highly hydrophilic, meaning it dissolves readily in water and crosses lipid membranes poorly, and a 2008 program conjugated it to lipid and sugar groups to improve permeability [26]. The conjugates resisted enzymatic hydrolysis in Caco-2 homogenates, several showed higher apparent permeability, and one released the parent dipeptide after crossing a Caco-2 monolayer [26]. An initial rat experiment examined absorption and bioavailability, and the abstract reports no result [26]. Hemolysis testing at 200 micromolar showed no toxicity to red blood cells [26].
Research in detail
Double-blind, randomized, placebo-controlled trial · Elderly patients scheduled for surgery on solid tumors of the abdominal cavity and retroperitoneal space
Thymogen restored the structural and functional parameters of cellular immunity, decreased the number and range of postoperative complications and shortened the postoperative period.
Evidence scope: Abstract reviewed; full text not read (article in Russian). Group sizes, complication rates, immune measurements and statistics are not reported in the abstract.
Clinico-epidemiological study in a training military unit · Personnel in a training military unit during influenza and acute respiratory infection season
Intranasal and subcutaneous Thymogen reduced the morbidity rate, severity and duration of influenza and other acute respiratory infections.
Evidence scope: Abstract reviewed; full text not read (article in Russian). Group sizes, attack rates and statistics are not reported, and the abstract does not state whether a placebo group was used.
Clinical and immunological study with healthy donor comparison · 48 patients with acute pancreatitis and 36 healthy donors
Including Thymogen in complex treatment corrected T-cell immune deficiency and produced positive clinical change.
Evidence scope: Abstract reviewed; full text not read (article in Russian). No randomization and no effect sizes are reported in the abstract; the comparison group was healthy donors, not a placebo arm.
Randomized phase II trial comparing two intranasal schedules · 44 patients with AIDS-related Kaposi sarcoma, median age 38, 75 percent with prior systemic chemotherapy
Major responses in 36 percent, five complete and 11 partial, after a median of 6 weeks and lasting a median of 33 or more weeks; adverse effects limited to mild, transient headache, fatigue, tingling and nausea.
Evidence scope: Abstract reviewed; full text not read. No placebo group, comparison of two schedules only, and most participants were taking protease inhibitors, which confounds the response rate.
Randomized, double-blind, placebo-controlled phase III trial over 24 weeks · 202 HIV-positive patients with AIDS-related Kaposi sarcoma, 104 on IM862 and 98 on placebo
Response rates were 23 percent on IM862 and 21 percent on placebo (P=.46); time to response was 8.5 versus 14 weeks (P=.024) and median time to progression 16 versus 35 weeks (P=.012).
Evidence scope: Abstract reviewed; full text not read. The authors conclude that IM862 was not superior to placebo and may accelerate progression; baseline antiretroviral use differed between arms, 88 versus 96 percent.
Prospective single-arm phase II trial with a standard two-step design · 25 patients with metastatic renal cell carcinoma, median age 62
No objective responses, eight patients with stable disease and 17 with progression; median survival 7.9 months; no grade 2 or 3 toxicity; plasma vascular endothelial growth factor fell at 4 and 8 weeks.
Evidence scope: Abstract reviewed; full text not read. Single-arm and small, and the authors recommend no further evaluation of IM862 as a single agent at this dose and schedule in this population.
Phase I dose-escalation study, registry record · Patients with recurrent ovarian cancer after chemotherapy and surgery; 43 enrolled
The registry lists the study as completed in August 2001 with 43 participants; no results are posted.
Evidence scope: Registry record reviewed; no results posted.
Randomized, placebo-controlled, double-blind phase II study, registry record · Patients with metastatic colorectal cancer; 18 enrolled
The registry lists the study as terminated in November 2001 because the drug was not available; no results are posted.
Evidence scope: Registry record reviewed; no results posted.
Randomized phase II trial with consolidation therapy, registry record · Patients with newly diagnosed advanced epithelial ovarian or primary peritoneal cancer after resection
The registry lists the study as started in January 2001 with unknown status and no posted results.
Evidence scope: Registry record reviewed; no results posted. Enrollment is not recorded.
History and where it stands today
Thymogen followed an unusual path: a calf-thymus extract turned into a defined dipeptide, a Russian clinical drug, and an American cancer program that ended in a negative phase III trial.
- 1993A clinico-epidemiological study in a training military unit reported that intranasal and subcutaneous Thymogen reduced the rate, severity and duration of influenza and other acute respiratory infections [13].
- 1997Morozov and Khavinson reported isolating the dipeptide from the calf-thymus complex Thymalin and designing the synthetic drug Thymogen on the synthesized molecule [1].
- 2000A lifetime rat study found that 5 micrograms per rat given five times a week for 12 months raised the maximum lifespan of the longest-lived 10 percent from 949 to 1048 days and lowered spontaneous tumor incidence [2].
- 2000A randomized phase II trial of intranasal IM862 in 44 patients with AIDS-related Kaposi sarcoma reported major responses in 36 percent, with mild headache, fatigue, tingling and nausea as the main adverse effects [15].
- 2003Mouse work showed that the antitumor effect of the dipeptide requires NK cells and perforin, which gave the molecule a defined immune mechanism [6].
- 2004A phase II trial of intranasal IM862 in 25 patients with metastatic kidney cancer recorded no objective responses and no grade 2 or 3 toxicity [17].
- 2005The 202-patient phase III trial found no response advantage over placebo, 23 versus 21 percent, and a shorter time to progression on IM862, 16 versus 35 weeks [16].
- 2009Thymogen received Russian Ministry of Health registration certificate P N002408/01 dated June 10, 2009 [3].
- 2011A double-blind, randomized, placebo-controlled trial in elderly patients having abdominal cancer surgery reported restored cellular immunity and fewer postoperative complications after seven days of intranasal Thymogen [12].
- October 2026The 2024 review records Thymogen's Russian registration [3]. As of October 2026, it has no FDA approval on record and no place on FDA's Category 2 list [25][24], and neither the 2026 WADA list nor the NCAA 2026-27 list names it [22][23].
How it compares with related peptides
Thymalin is the calf-thymus peptide complex from which the Thymogen dipeptide was isolated, so the two are a mixture and its defined component rather than rivals [1][2]. Thymalin entered practice first as an immune corrector, and Thymogen was designed as the synthetic, single-molecule version [1]. Thymalin has no single amino-acid length because it is an extract, while Thymogen is exactly two amino acids [1]. The Thymalin page covers the parent complex.
Vilon is the other synthetic thymic dipeptide from the same group, and the 1997 report introduced it alongside Thymogen [1]. Both are two amino acids long and both were studied for immune restoration [1][4]. The 2022 monocyte study tested both; both lowered lipopolysaccharide-driven tumor necrosis factor and interleukin-6, while Vilon had little effect on ERK1/2 phosphorylation [4]. See Vilon for its record.
Epitalon is a tetrapeptide of four amino acids that the same group isolated from animal tissue, and the same 2022 monocyte study tested it beside Thymogen [4]. Thymogen and three of the other four peptides raised mitogen-activated protein kinase phosphorylation, and all five lowered lipopolysaccharide-driven tumor necrosis factor and interleukin-6, so the shared cytokine effect is not specific to Thymogen [4]. Thymogen was derived from calf thymus and Epitalon from bovine pineal gland, which is where the organ-specific idea behind this peptide family comes from [4]. The Epitalon page covers that literature.
Side effects and safety signals
The safety record comes from small Russian studies and from the American IM862 trials, and it is short on modern toxicology.
- Mild, transient headache, fatigue, tingling and nausea: the 44-patient Kaposi sarcoma trial attributed only these to intranasal IM862, with no hematologic toxicity [15].
- No grade 2 or 3 toxicity: the 25-patient kidney cancer trial recorded none related to the drug, although 17 of 25 patients progressed on treatment [17].
- A possible harm signal: in the phase III Kaposi sarcoma trial, median time to progression was shorter on IM862, 16 versus 35 weeks, and the authors wrote that the drug may accelerate progression [16].
- Immune stimulation carries a theoretical risk in cancer: the peptide slowed tumor growth in mice, but the phase III trial found a shorter time to progression on the drug, so the direction of the effect on a tumor is unresolved [6][16].
- Stereochemistry changes the safety question: the D-amino-acid isomer of the same dipeptide suppresses hematopoietic progenitors, so the D form would not have the same biology [7][3].
- The toxicology file is thin: the sources reviewed report no repeat-dose toxicity, genotoxicity or reproductive study of Thymogen, and the tumor data come from one lifetime rat study [2].
- Identity and purity are the practical checks for a two-amino-acid peptide, and the COA library tracks the tests vendors publish.
The future: what's next for Thymogen
No trial of Thymogen or oglufanide is recruiting in ClinicalTrials.gov. A ClinicalTrials.gov search for IM862 on October 23, 2026 returned four records, and none is recruiting: a completed 43-patient phase I study in recurrent ovarian cancer (NCT00003773), a phase II colorectal study terminated because the drug was unavailable (NCT00006037), and a phase II ovarian and peritoneal study with unknown status (NCT00017303) [18][19][20]. The fourth is the completed phase III Kaposi sarcoma study (NCT00002445; 200 enrolled in the registry) [21]. The ovarian and colorectal studies were sponsored by the University of Southern California [18][19], and the ovarian and Kaposi studies by Cytran [20][21].
The research frontier is formulation and analogues. Lipid and sugar conjugates of the dipeptide improved permeability and enzymatic stability in Caco-2 models, and one released the parent peptide after crossing the monolayer, a step toward an oral form [26]. D-alanine analogues at the C-terminus outperformed Thymogen in two liver-injury models, so the pharmacophore has room to improve [8][9]. Neither line has reached a registered trial in the sources reviewed.
The biology still needs a mechanism. The chromatin-binding proposal in the 2024 review has not been tested in an independent system in the sources reviewed [3], and the NK-cell requirement is the only mechanism in these sources backed by gene-knockout experiments [6]. A binding assay or chromatin assay that reproduces the effect would let chemists design a better dipeptide instead of testing analogues one at a time [3][8].
Russian clinical use is documented in the 2024 review, and the 2011 surgical study remains the only double-blind, placebo-controlled Russian trial in the sources reviewed; its abstract reports no group sizes or effect estimates [3][12]. A properly powered trial in chemotherapy-induced neutropenia, the setting the 2024 review discusses, would be the most direct test of the immune-restoration claim [3].
- How Thymogen signals through CD4 and CD8 on T cells, and whether its chromatin binding matters, remain open questions [3].
- Whether the Russian immune-restoration results survive a properly powered, blinded trial is unresolved [12][14].
- Whether the peptide helps or harms in cancer is unsettled, because it slowed tumors in mice but shortened time to progression in the phase III Kaposi trial [6][16].
- How much intact dipeptide reaches the blood after oral dosing has not been reported in the sources reviewed [26].
- Whether D-alanine analogues are safer or simply more potent is untested in humans [8][9].